Skip to main content
BCDA
NASDAQ Life Sciences

BioCardia Q3: $2.2M Cash, Going Concern Doubt Beyond January 2027, ATM Exhausted

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.831
Mkt Cap
$12.505M
52W Low
$0.661
52W High
$1.8
52W Position info
26% above low
Off High info
54% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

BCDA sits 26% above its 52-week low of $0.661.

Summary

BioCardia reported $2.2 million of cash at September 30, 2026 and said it cannot fund operations past January 2027, with its ATM fully used and no shares left to sell under the current shelf.


Key Events · Earnings and Guidance · BCDA

  • Going Concern Warning on Thin Cash

    Cash and equivalents were $2.224 million at September 30, 2026, down from $2.496 million at December 31, 2025, and management says this is not sufficient to fund planned expenditures and meet obligations beyond January 2027, raising substantial doubt about the ability to continue as a going concern.

  • ATM Fully Exhausted, No Shelf Left

    The company sold 4,189,055 shares under the H.C. Wainwright ATM in the first nine months of 2026 for $5.309 million gross, and reports no capacity to issue shares under the ATM prospectus supplement as of September 30, 2026 and November 12, 2026.

  • Loss Narrows but R&D Steps Up

    Nine-month net loss was $5.689 million versus $6.244 million a year earlier, while third-quarter R&D rose to $1.235 million from $936,000 on higher bonus accrual and spending to advance CardiAMP in Japan and enroll the HF II trial.

  • Funding Must Come From New Sources

    With the ATM closed, management plans to raise capital through non-dilutive collaboration and licensing arrangements, debt or equity financing, and warns that any equity raised may be on highly dilutive terms.


Analysis · BCDA · Life Sciences

BioCardia ended September 30, 2026 with $2.2 million in cash and no remaining capacity under its at-the-market facility, and management states plainly that this is not enough to fund operations beyond January 2027. That leaves roughly two months of runway from today, and with no shelf left to sell into, any new money must come from a fresh registration, a licensing deal, or debt. The operating loss is narrowing ($5.7M for nine months vs $6.3M a year ago) and R&D is being redirected toward Japanese and U.S. regulatory filings, but the balance sheet, not the pipeline, is the binding constraint. The next hard date is the January 2027 cash wall; the nearest regulatory item is FDA feedback on the Helix De Novo pre-submission, which the company expects within about five weeks.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BCDA was trading at $0.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.5M. The 52-week trading range was $0.66 to $1.80. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BCDA - Latest Insights

BCDA
Oct 07, 2026, 9:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.10
Real-time Price: $0.7801 info
Change: -$0.316 (-29%) info
Market Cap: $12.58M info
BCDA
Aug 24, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.980
Real-time Price: $0.7801 info
Change: -$0.1999 (-20%) info
Market Cap: $12.58M info
BCDA
Aug 21, 2026, 4:34 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.01
Real-time Price: $0.7801 info
Change: -$0.2299 (-23%) info
Market Cap: $12.58M info
BCDA
Aug 12, 2026, 4:27 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.902
Real-time Price: $0.7801 info
Change: -$0.1219 (-14%) info
Market Cap: $12.58M info
BCDA
Aug 12, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.870
Real-time Price: $0.7801 info
Change: -$0.0899 (-10%) info
Market Cap: $12.58M info